75 results about "Asenapine" patented technology

Compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia and manic or mixed episodes associated with bipolar I disorder with or without psychotic features is disclosed:

wherein R₁-R₈, G, N and A⁻ are as defined in the written description.

Provided is a skin irritation suppressant for transdermal preparations, having a sufficient reduction effect of skin irritation due to a drug. Also provided is a transdermal preparation comprising the skin irritation suppressant. One embodiment of the invention is a skin irritation suppressant for suppressing the skin irritation due to a drug and a pharmaceutical ingredient to be used in a transdermal preparation other than the drug, the skin irritation suppressant comprising a sterol compound selected from the group consisting of cholesterol, cholesterol derivatives and cholesterol analogs, and the drug is one or more basic drugs selected from the group consisting of tolterodine, asenapine, bisoprolol, risperidone, nicotine and citalopram, and their pharmaceutically acceptable salts.

Asenapine or a pharmaceutically acceptable salt thereof can be administered intranasally, typically via an intranasal dosage formulation having a water-containing liquid carrier.

The invention discloses a process for synthesis of asenapine. The asenapine is prepared through adopting a compound (18) as a key intermediate and carrying out the following steps that: 1.1, the compound 18 is subjected to a Ullmann reaction under a alkaline condition through adopting copper powder as a catalyst to generate a ether (19); 1.2, the ether (19) is subjected to a carbonyl reduction to obtain the target compound of the asenapine (1). The process has the following advantages that: cheap and available 2-bromobenzaldehyde is adopted as an initial raw material and is subjected to acondensation, a addition, a reductive amination and a intramolecular cyclization reaction, a aminomethylation, a open loop transposition and then loop closing, a demethylation and a Ullmann loop closing reaction to synthesize of the asenapine (1); cis-trans-isomer is subjected to a delicate transposition to obtain a trans-product, such that the process is simplified and easy to be operated; the raw material is easy to be obtained and has cheap price; each reaction is a normal reaction, and reaction conditions are mild; a total yield is substantially improved; production cost is reduced; a purity of the product is more than 99% through a detection by HPLC.

The invention provides a spongy asenapine sublingual film agent with micropores and a preparation method thereof. The film agent comprises asenapine, water-soluble macromolecular materials and water-insoluble micro powder dispersed in the water-soluble macromolecular materials, wherein the molecular weight of at least one of the water-soluble macromolecular materials is 10000 to 200000 daltons, and the molecular weight of at least one of the water-soluble macromolecular materials is 200000 to 10000000 daltons. The film agent has a very remarkable effect, the film is quickly dissolved through the macromolecular material with low molecular weight, and the physical strength and the toughness of the film are ensured through the macromolecular material with high molecular weight, so that the aim of quick release is fulfilled and the strength of the film is ensured.

The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising a self-adhesive layer structure containing a therapeutically effective amount of asenapine, such asenapine TTS for use in a method of treatment, processes of manufacture of such TTS as well as asenapine and transdermal therapeutic systems containing asenapine for use in a method of treatment and to a method of treating a human patient by transdermal administration of asenapine.

The invention relates to a preparation method of a psychotropic medicine asenapine. The method comprises a step that asenapine is prepared through a reaction of a raw material trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-monobenzo[2,3:6,7]oxepino[4,5-C]pyrrole-1-one or trans-11-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenzo[2,3:6,7]oxepino[4,5-C]pyrrole-1-one under the action of a reducing agent sodium bisaluminumhydride or a composite reducing agent composed of sodium bisaluminumhydride and other regents. The method has the advantages of mild and controllable reaction technology, low production cost, good product yield, realization of the large scale application in the industrial production, and good enforcement values and social and economic benefits.

The invention concerns methods of treating suicidal ideation or behavior in a subject in need thereof, comprising decreasing endogenous nicotinic acetylcholine receptor (nAChR) activity in the subject; therapeutic packages for treating suicidal ideation or behavior; and methods for determining the efficacy of a treatment for suicidal ideation or behavior. In some embodiments, the treatment methods comprise administering to the subject an effective amount of an inhibitor of a nAChR, such as a lithium compound, mecamylamine, clozapine, or asenapine.

The present invention relates to liquid compositions of asenapine with one or more pharmaceutically acceptable excipients. More particularly, the present invention relates to liquid spray compositions comprising asenapine for administration through oral mucosa.

The invention relates to a method for preparing asenapine shown in a general formula (9) and an intermediate shown in a general formula (7) and used for preparing asenapine. The general formulas are shown in the specification. The method comprises the step that asenapine shown in the general formula (9) is obtained through ring-closure reaction of a compound shown in a general formula (8).

The present invention provides a formulation comprising asenapine hemipamoate suspended particles, which formulation can be administered via a Depot provided by an IM injection of the formulation, and which depot does not display a particle-size dependent release rate. The present invention provides also methods of treatment using the same.

The invention discloses an asenapine slow-release microsphere agent and a preparation method thereof. The microsphere agent is prepared from asenapine or salts and polyesters thereof, wherein the weight percentage of the asenapine or salts thereof counted by asenapine is 5-50%, and the weight percentage of the polyesters is 50-95%. The preparation method comprises the following steps: (1) conducting weighing; (2) adding the polyester material into an organic solvent for completely dissolving the polyester material to obtain a settled solution, then dissolving or suspending the medicine asenapine or the salts thereof into the settled solution to be used as an oil phase; stirring or shearing the oil phase at high speed to form a homogeneous oil phase; and in case of need, adding a right amount of acid for salifying the asenapine; and (3) preparing the microsphere agent by a microdroplet generating device, or a spray drying method, or an atomizing extraction method. The microsphere agent provided by the invention has relatively high production efficiency, the D50 particle sizes of the prepared microspheres are all below 80mu m, are controllable and are concentrated in distribution, the drug-loading rate is as high as 45%, and the encapsulation rate is above 85%.

The invention belongs to the field of pharmaceutical chemistry, and provides a preparation method of an asenapine key impurity (IV) trans-5-chloro-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole. The trans-5-chloro-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole is prepared from trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole used as the initial raw material. The impurity is a very key impurity for synthesizing asenapine, and is also an important intermediate for controlling the asenapine end product quality standard.

Belonging to the medical technology field, the invention in particular relates to a maleic acid asenapine compound and a preparation method thereof. The invention also relates to application of compositions containing the maleic acid asenapine compound in preparation of drugs treating antipsychotic drugs.

The invention belongs to the field of pharmaceutical chemistry, and relates to a refining method of an asenapine important intermediate 11-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrryl-1-one. The refining method is simple to operate, can easily implement industrial production, and enhances the yield by nearly 20% relative to reported documents.

The present invention provides a process for the preparation of the asenapine intermediate of Formula (III) using a magnesium-methanol-acetic acid mixture.

The invention discloses a method for purifying asenapine. The method carries out crystallization and purification through two different crystallization systems, and adopts a low-temperature drying method to purify asenapine. The purity of asenapine in the purified product reaches 99.9% % above, the total impurity content does not exceed 0.1%, and does not contain adsorbed water.